R R

What Is Pegcetacoplan Ophthalmic?

Pegcetacoplan ophthalmic is a prescription medication administered through an injection into the eye to treat geographic atrophy secondary to age-related macular degeneration. It is marketed under the brand name Syfovre and belongs to the complement inhibitor class. Geographic atrophy involves progressive damage to cells in the retina, which can cause areas of permanent vision loss. Pegcetacoplan acts on the complement system to slow the growth of retinal lesions. It does not cure age-related macular degeneration or restore retinal tissue that has already been lost.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Pegcetacoplan Ophthalmic?

Pegcetacoplan ophthalmic is a prescription medication administered through an injection into the eye to treat geographic atrophy secondary to age-related macular degeneration. It is marketed under the brand name Syfovre and belongs to the complement inhibitor class. Geographic atrophy involves progressive damage to cells in the retina, which can cause areas of permanent vision loss. Pegcetacoplan acts on the complement system to slow the growth of retinal lesions. It does not cure age-related macular degeneration or restore retinal tissue that has already been lost.

read more about pegcetacoplan ophthalmic ...

Copy this HTML:

Copy HTML Copied!

How Does Pegcetacoplan Ophthalmic Work?

Pegcetacoplan binds to complement protein C3 and inhibits its activation. The complement system participates in immune responses and inflammatory processes associated with geographic atrophy. By blocking C3 activity, pegcetacoplan reduces signaling through several complement pathways that may contribute to retinal damage. Clinical studies have shown that treatment can slow the enlargement of geographic atrophy lesions. However, reducing lesion growth does not necessarily result in noticeable improvement in existing vision, and treatment cannot reverse established retinal cell loss.

What Eye Condition Does Pegcetacoplan Ophthalmic Treat?

Pegcetacoplan ophthalmic is approved for geographic atrophy secondary to age-related macular degeneration. Geographic atrophy is an advanced form of dry age-related macular degeneration involving gradual loss of retinal pigment epithelial cells and photoreceptors. It can affect central or surrounding vision depending on lesion location and progression. An ophthalmologist evaluates retinal imaging, disease activity, and other eye conditions before recommending treatment. Pegcetacoplan is not approved as a treatment for ordinary dry eyes, refractive errors, or general vision changes caused by aging.

How Is Pegcetacoplan Ophthalmic Administered?

Syfovre is administered by an ophthalmologist through an intravitreal injection, which places medication into the vitreous cavity of the eye. The recommended dose is 15 mg in 0.1 mL injected into each affected eye once every 25 to 60 days. The clinician uses appropriate sterile techniques and monitors for injection-related complications. Treatment frequency is individualized within the approved interval. Patients should follow post-injection care instructions and immediately report worsening vision, significant eye pain, or unusual redness. Contact lens wear after an injection should follow the treating ophthalmologist's directions.

What Are the Side Effects and Warnings of Pegcetacoplan Ophthalmic?

Common adverse effects include eye discomfort, vitreous floaters, conjunctival bleeding, and the development of neovascular age-related macular degeneration. Serious risks include endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, and increased intraocular pressure. Retinal vasculitis or vascular occlusion can cause severe vision loss and has been reported after the first injection. Pegcetacoplan should not be administered to patients with active ocular or surrounding infections or active intraocular inflammation. New floaters, flashing lights, severe pain, or sudden vision changes require urgent ophthalmic assessment.

Common Questions About Pegcetacoplan Ophthalmic

Is pegcetacoplan ophthalmic the same as Syfovre?

Yes. Syfovre is the brand name for pegcetacoplan injection administered into the eye to treat geographic atrophy secondary to age-related macular degeneration.

Can pegcetacoplan restore lost vision?

Pegcetacoplan can slow the enlargement of geographic atrophy lesions, but it does not restore retinal tissue that has already been lost or guarantee improved visual acuity.

How frequently are Syfovre injections given?

The recommended dose is administered into each affected eye once every 25 to 60 days. An ophthalmologist determines the treatment schedule.

Can contact lenses be worn after a pegcetacoplan injection?

Patients should follow their ophthalmologist's instructions about resuming contact lens wear after an intravitreal injection. Contact lenses should not be inserted when the eye is painful, red, or otherwise irritated.

References

DailyMed - SYFOVRE (pegcetacoplan) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4434e61-9ec9-4e0e-bd60-45aaa0a87e64. Date Accessed October 30, 2026.

Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. Clinical Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/40371972/. Date Accessed October 30, 2026.

Pegcetacoplan for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration (OAKS and DERBY): Two Multicentre, Randomised, Double-Masked, Sham-Controlled, Phase 3 Trials. The Lancet. https://pubmed.ncbi.nlm.nih.gov/37865470/. Date Accessed October 30, 2026.

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/40280279/. Date Accessed October 30, 2026.

Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. Journal of VitreoRetinal Diseases. https://pubmed.ncbi.nlm.nih.gov/38223782/. Date Accessed October 30, 2026.